A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

When we think of cancer, we often focus on the big symptoms, but colorectal cancer comes with side effects that don’t always ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Artemisia herba-alba shows promise in combating colorectal cancer, offering new hope through its powerful medicinal ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III ...

After this treatment, they typically receive adjuvant chemotherapy intended ... that anti-inflammatory drugs might benefit some patients with colon cancer, but not others. One possibility for ...